Decompensated islet beta cell function in patients with chronic hepatitis B: a retrospective case-control study
Dysglycometabolism is often accompanied with decreased islet β cell function based on the homeostasis model assessment of β cell function (HOMA-β). In this study, we aimed to identify the difference in HOMA-β values between Chronic hepatitis B (CHB) and non-hepatitis B virus (non-HBV) patients.Methods The study included 110 CHB and 110 non-HBV patients matched according to gender, age, and body mass index. HOMA-β values were evaluated.Results Under the normal glucose tolerance(NGT) condition,
... e(NGT) condition, the HOMA-β value of the CHB group was in the decompensated stage, and HOMA-β value of CHB was always lower than non-HBV patients (NGT, impaired glucose regulation, and diabetes mellitus: 47.53vs.124.19, 41.59vs.80.17, and 36.46vs.62.92mIU/mmol; t =−4.709, −2.042, and −2.091; P=0.000, 0.047, and 0.046, respectively).Conclusion Clinicians should focus on dysglycometabolism of patients with CHB. Background Chronic hepatitis B(CHB) has affected about 300 million people worldwide 1 , of whom about 650,000 die of hepatic failure, liver cirrhosis(LC), and hepatocellular carcinoma (HCC) annually 2 . China is one of the HBV middle-and low-endemic areas worldwide, approximately 93 million people are infected with HBV, among them, 20 million present with CHB 1,3. Although the relationship between hepatitis B virus(HBV) infection and diabetes mellitus(DM) remains unclear, several studies have shown that the prevalence of DM is significantly high in the HBVinfected population 4,5 , particularly in those with high viral load, long duration of CHB, cirrhosis 4,6,7 , and Asian Americans 8 . Our previous study has shown that 59.09% of CHB patients have high homeostasis model assessment of insulin resistance(HOMA-IR) values and that 93.64% of individuals have low homeostasis model assessment of β cell function(HOMA-β) value. Moreover, 35.45% of individuals have impaired glucose tolerance(IGT) 9-11 , which indicated that the prevalence of dysglycometabolism and insulin resistance(IR) is high in patients with CHB.